Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium breve is a probiotic bacterium that has been investigated for its potential role in managing symptoms of Irritable Bowel Syndrome (IBS). The scientific rationale for its use is grounded in the understanding that the gut microbiota can influence gastrointestinal function and symptoms in IBS. Several clinical studies, including randomized, placebo-controlled trials, have evaluated the efficacy of Bifidobacterium breve strains (such as B. breve M-16V and B. breve Yakult) in reducing symptoms like abdominal pain, bloating, and irregular bowel movements. Some studies have shown modest benefits, particularly in improving global IBS symptoms and quality of life, although results are not universally consistent across all research. Meta-analyses of probiotics in IBS generally find that Bifidobacterium species, including B. breve, may be beneficial, but they are often studied as part of multi-strain formulations, making it difficult to attribute effects solely to B. breve. The proposed mechanisms include modulation of the immune response, strengthening the intestinal barrier, and altering gut motility and sensitivity. Overall, while the evidence is not definitive and more high-quality, strain-specific research is needed, there is a moderate level of scientific validation for the use of Bifidobacterium breve in supporting IBS symptom management.

More about bifidobacterium breve
More about Irritable Bowel Syndrome

Other ingredients used for Irritable Bowel Syndrome

Other health conditions supported by bifidobacterium breve

Products containing bifidobacterium breve